Literature DB >> 32634120

The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.

Sravanthi Lavu1, Lisa E Vaughan2, Sarah R Senum1, Timothy L Kline3, Arlene B Chapman4,5, Ronald D Perrone6, Michal Mrug7, William E Braun8, Theodore I Steinman9, Frederic F Rahbari-Oskoui5, Godela M Brosnahan10, Kyongtae T Bae11, Douglas Landsittel12, Fouad T Chebib1, Alan Sl Yu13, Vicente E Torres1, Peter C Harris1.   

Abstract

BACKGROUNDA treatment option for autosomal dominant polycystic kidney disease (ADPKD) has highlighted the need to identify rapidly progressive patients. Kidney size/age and genotype have predictive power for renal outcomes, but their relative and additive value, plus associated trajectories of disease progression, are not well defined.METHODSThe value of genotypic and/or kidney imaging data (Mayo Imaging Class; MIC) to predict the time to functional (end-stage kidney disease [ESKD] or decline in estimated glomerular filtration rate [eGFR]) or structural (increase in height-adjusted total kidney volume [htTKV]) outcomes were evaluated in a Mayo Clinic PKD1/PKD2 population, and eGFR and htTKV trajectories from 20-65 years of age were modeled and independently validated in similarly defined CRISP and HALT PKD patients.RESULTSBoth genotypic and imaging groups strongly predicted ESKD and eGFR endpoints, with genotype improving the imaging predictions and vice versa; a multivariate model had strong discriminatory power (C-index = 0.845). However, imaging but not genotypic groups predicted htTKV growth, although more severe genotypic and imaging groups had larger kidneys at a young age. The trajectory of eGFR decline was linear from baseline in the most severe genotypic and imaging groups, but it was curvilinear in milder groups. Imaging class trajectories differentiated htTKV growth rates; severe classes had rapid early growth and large kidneys, but growth later slowed.CONCLUSIONThe value of imaging, genotypic, and combined data to identify rapidly progressive patients was demonstrated, and reference values for clinical trials were provided. Our data indicate that differences in kidney growth rates before adulthood significantly define patients with severe disease.FUNDINGNIDDK grants: Mayo DK058816 and DK090728; CRISP DK056943, DK056956, DK056957, and DK056961; and HALT PKD DK062410, DK062408, DK062402, DK082230, DK062411, and DK062401.

Entities:  

Keywords:  Genetic diseases; Genetics; Nephrology

Mesh:

Substances:

Year:  2020        PMID: 32634120      PMCID: PMC7455088          DOI: 10.1172/jci.insight.138724

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  46 in total

1.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

3.  Evidence of extraordinary growth in the progressive enlargement of renal cysts.

Authors:  Jared J Grantham; Larry T Cook; Louis H Wetzel; Melissa A Cadnapaphornchai; Kyongtae T Bae
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-01       Impact factor: 8.237

4.  Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Alan S L Yu; Chengli Shen; Douglas P Landsittel; Peter C Harris; Vicente E Torres; Michal Mrug; Kyongtae T Bae; Jared J Grantham; Frederic F Rahbari-Oskoui; Michael F Flessner; William M Bennett; Arlene B Chapman
Journal:  Kidney Int       Date:  2017-12-28       Impact factor: 10.612

5.  Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; J A Breyer; G J Beck; V W Dennis; J A Hartman; D Roth; T I Steinman; S R Wang; M E Yamamoto
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

6.  Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.

Authors:  Edwin M Spithoven; Anneke Kramer; Esther Meijer; Bjarne Orskov; Christoph Wanner; Jose M Abad; Nuria Aresté; Ramón Alonso de la Torre; Fergus Caskey; Cécile Couchoud; Patrik Finne; James Heaf; Andries Hoitsma; Johan de Meester; Julio Pascual; Maurizio Postorino; Pietro Ravani; Oscar Zurriaga; Kitty J Jager; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

7.  Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium.

Authors: 
Journal:  Cell       Date:  1995-04-21       Impact factor: 41.582

8.  Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Young-Hwan Hwang; John Conklin; Winnie Chan; Nicole M Roslin; Jannel Liu; Ning He; Kairong Wang; Jamie L Sundsbak; Christina M Heyer; Masoom Haider; Andrew D Paterson; Peter C Harris; York Pei
Journal:  J Am Soc Nephrol       Date:  2015-10-09       Impact factor: 10.121

Review 9.  A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Authors:  Fouad T Chebib; Ronald D Perrone; Arlene B Chapman; Neera K Dahl; Peter C Harris; Michal Mrug; Reem A Mustafa; Anjay Rastogi; Terry Watnick; Alan S L Yu; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2018-09-18       Impact factor: 10.121

10.  Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Christina M Heyer; Jamie L Sundsbak; Kaleab Z Abebe; Arlene B Chapman; Vicente E Torres; Jared J Grantham; Kyongtae T Bae; Robert W Schrier; Ronald D Perrone; William E Braun; Theodore I Steinman; Michal Mrug; Alan S L Yu; Godela Brosnahan; Katharina Hopp; Maria V Irazabal; William M Bennett; Michael F Flessner; Charity G Moore; Douglas Landsittel; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2016-01-28       Impact factor: 10.121

View more
  10 in total

1.  Assessing Risk of Progression in ADPKD.

Authors:  Craig E Gordon; Dana C Miskulin; Ronald D Perrone
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-09       Impact factor: 8.237

2.  Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Brian E Jones; Yaman G Mkhaimer; Laureano J Rangel; Maroun Chedid; Phillip J Schulte; Alaa K Mohamed; Reem M Neal; Dalia Zubidat; Amarjyot K Randhawa; Christian Hanna; Adriana V Gregory; Timothy L Kline; Ziad M Zoghby; Sarah R Senum; Peter C Harris; Vicente E Torres; Fouad T Chebib
Journal:  Kidney360       Date:  2021-12-07

3.  Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.

Authors:  Sarah R Senum; Ying Sabrina M Li; Katherine A Benson; Giancarlo Joli; Eric Olinger; Sravanthi Lavu; Charles D Madsen; Adriana V Gregory; Ruxandra Neatu; Timothy L Kline; Marie-Pierre Audrézet; Patricia Outeda; Cherie B Nau; Esther Meijer; Hamad Ali; Theodore I Steinman; Michal Mrug; Paul J Phelan; Terry J Watnick; Dorien J M Peters; Albert C M Ong; Peter J Conlon; Ronald D Perrone; Emilie Cornec-Le Gall; Marie C Hogan; Vicente E Torres; John A Sayer; Peter C Harris
Journal:  Am J Hum Genet       Date:  2021-12-09       Impact factor: 11.043

4.  The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease.

Authors:  Jennifer Arroyo; Diana Escobar-Zarate; Harrison H Wells; Megan M Constans; Ka Thao; Jessica M Smith; Cynthia J Sieben; Madeline R Martell; Timothy L Kline; Maria V Irazabal; Vicente E Torres; Katharina Hopp; Peter C Harris
Journal:  Kidney Int       Date:  2021-03-09       Impact factor: 18.998

5.  Characteristics of Patients with End-Stage Kidney Disease in ADPKD.

Authors:  Shehbaz S Shukoor; Lisa E Vaughan; Marie E Edwards; Sravanthi Lavu; Timothy L Kline; Sarah R Senum; Yaman Mkhaimer; Ghaith Zaatari; Maria V Irazabal; Reem Neal; Marie C Hogan; Ziad M Zoghby; Peter C Harris; Vicente E Torres; Fouad T Chebib
Journal:  Kidney Int Rep       Date:  2020-12-31

6.  Genomics Integration Into Nephrology Practice.

Authors:  Filippo Pinto E Vairo; Carri Prochnow; Jennifer L Kemppainen; Emily C Lisi; Joan M Steyermark; Teresa M Kruisselbrink; Pavel N Pichurin; Rhadika Dhamija; Megan M Hager; Sam Albadri; Lynn D Cornell; Konstantinos N Lazaridis; Eric W Klee; Sarah R Senum; Mireille El Ters; Hatem Amer; Linnea M Baudhuin; Ann M Moyer; Mira T Keddis; Ladan Zand; David J Sas; Stephen B Erickson; Fernando C Fervenza; John C Lieske; Peter C Harris; Marie C Hogan
Journal:  Kidney Med       Date:  2021-06-29

7.  An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.

Authors:  Roman-Ulrich Müller; A Lianne Messchendorp; Henrik Birn; Giovambattista Capasso; Emilie Cornec-Le Gall; Olivier Devuyst; Albertien van Eerde; Patrick Guirchoun; Tess Harris; Ewout J Hoorn; Nine V A M Knoers; Uwe Korst; Djalila Mekahli; Yannick Le Meur; Tom Nijenhuis; Albert C M Ong; John A Sayer; Franz Schaefer; Aude Servais; Vladimir Tesar; Roser Torra; Stephen B Walsh; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2022-04-25       Impact factor: 7.186

8.  Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease.

Authors:  Javier Naranjo; Mónica Furlano; Ferran Torres; Jonathan Hernandez; Marc Pybus; Laia Ejarque; Christian Cordoba; Lluis Guirado; Elisabet Ars; Roser Torra
Journal:  Clin Kidney J       Date:  2021-12-28

9.  Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan.

Authors:  Ramón Peces; Rocío Mena; Carlos Peces; Emilio Cuesta; Pablo Lapunzina; Rafael Selgas; Julián Nevado
Journal:  Clin Kidney J       Date:  2021-04-25

10.  Rapidly Progressing to ESRD in an Individual with Coexisting ADPKD and Masked Klinefelter and Gitelman Syndromes.

Authors:  Ramón Peces; Carlos Peces; Rocío Mena; Emilio Cuesta; Fe Amalia García-Santiago; Marta Ossorio; Sara Afonso; Pablo Lapunzina; Julián Nevado
Journal:  Genes (Basel)       Date:  2022-02-23       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.